Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada 2026 Inflammatory Bowel Disease (IBD) Fellowship- United StatesRelease Date:Fellowship Inflammation & Immunology USA Title Grant Type Focus Area Country Application Due Date Clinical Updates and Strategies in the Treatment and Management of First-line BRAF V600E-mutant Metastatic Colorectal CancerRelease Date:Education Oncology USA Guidelines and Best Practices in the Holistic Management of Patients with Metastatic Urothelial Carcinoma (mUC)Education Oncology USA Improving Atopic Dermatitis and Alopecia Areata Quality of Care to Standardize ManagementRelease Date:Partner: Beijing Guangda Precision Medicine Research CenterQuality Improvement Inflammation & Immunology China COVID-19 Disease Burden on the Pediatric PopulationRelease Date:Education Vaccines USA Post-COVID Conditions: Potential Diagnosis, Testing, Management, and Ongoing ResearchRelease Date:Education Vaccines USA Optimizing Antimicrobial Stewardship Program in Saudi ArabiaRelease Date:Quality Improvement Inflammation & Immunology Saudi Arabia Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology All Pharmacokinetics-pharmacodynamics (PK-PD) of aztreonam-avibactam (ATM-AVI) in Special PopulationsRelease Date:Research Inflammation & Immunology Austria, Denmark, Finland, Germany, Italy, Netherlands, Norway, Romania, Spain, Sweden, United Kingdom Invasive Mold Infections (IMI) - Real-World Evidence from Treatment Outcomes with IsavuconazoleRelease Date:Research Inflammation & Immunology Australia, Germany, Israel, Italy, Spain, Switzerland Optimizing maternal immunization practice in Malaysia Indonesia Singapore PhilippinesRelease Date:Quality Improvement Vaccines Indonesia, Malaysia, Philippines, Singapore PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate CancerRelease Date:Education Oncology USA